Fortress Biotech Announces Exclusive Worldwide License Agreement With Columbia University to Develop Novel Oligonucleotide Platform for the Treatment of Genetically Driven Cancers Nasdaq:FBIO

  • Gary Schwartz

Press/Media

Period8 May 2020

Media coverage

1

Media coverage

  • TitleFortress Biotech Announces Exclusive Worldwide License Agreement With Columbia University to Develop Novel Oligonucleotide Platform for the Treatment of Genetically Driven Cancers Nasdaq:FBIO
    Media name/outletGlobal English (Middle East and North Africa Financial Network)
    Country/TerritoryJordan
    Date8/05/20
    PersonsGary Schwartz
View all 1
View less